DOSTARLIMAB for Cervix neoplasm: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 51 adverse event reports in the FDA FAERS database where DOSTARLIMAB was used for Cervix neoplasm.
Most Reported Side Effects for DOSTARLIMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Malignant neoplasm progression | 111 | 12.4% | 38 | 17 |
| Thrombocytopenia | 42 | 4.7% | 0 | 17 |
| Fatigue | 38 | 4.3% | 1 | 12 |
| Anaemia | 36 | 4.0% | 9 | 17 |
| Death | 31 | 3.5% | 31 | 3 |
| Arthralgia | 30 | 3.4% | 1 | 9 |
| Diarrhoea | 29 | 3.3% | 3 | 14 |
| Rash | 29 | 3.3% | 0 | 14 |
| Condition aggravated | 27 | 3.0% | 7 | 14 |
| Dyspnoea | 26 | 2.9% | 2 | 20 |
| Nausea | 26 | 2.9% | 6 | 13 |
| Neuropathy peripheral | 26 | 2.9% | 2 | 4 |
| Abdominal pain | 25 | 2.8% | 3 | 20 |
| Off label use | 24 | 2.7% | 3 | 7 |
| Pyrexia | 24 | 2.7% | 2 | 16 |
Other Indications for DOSTARLIMAB
Endometrial cancer (315)
Ovarian cancer (119)
Endometrial cancer recurrent (115)
Neoplasm (106)
Non-small cell lung cancer (51)
Product used for unknown indication (39)
Endometrial neoplasm (29)
Breast cancer (25)
Endometrial adenocarcinoma (25)
Endometrial cancer metastatic (16)